Marinus Pharmaceuticals downgraded to Hold from Buy at TD Cowen
The Fly

Marinus Pharmaceuticals downgraded to Hold from Buy at TD Cowen

TD Cowen analyst Joseph Thome downgraded Marinus Pharmaceuticals (MRNS) to Hold from Buy without a price target after the Phase III trial of ganaxolone in tuberous sclerosis complex failed to meet the primary endpoint. The firm cites the company’s given cash constraints and unclear timing on next steps for the downgrade.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App